Clinical trial NCT02624037 - References

Inflammatory Bowel Disease — Precision IFX: Using a Dashboard to Individualize Infliximab Dosage

Citation(s)

•   Barrett JS, Mondick JT, Narayan M, Vijayakumar K, Vijayakumar S
  Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Med Inform Decis Mak. 2008 Jan 28;8:6. doi: 10.1186/1472-6947-8-6.
•   Baumgart DC, Carding SR
  Inflammatory bowel disease: cause and immunobiology. Lancet. 2007 May 12;369(9573):1627-40. Review.
•   Billioud V, Sandborn WJ, Peyrin-Biroulet L
  Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011 Apr;106(4):674-84. doi: 10.1038/ajg.2011.60. Epub 2011 Mar 15. Review.
•   Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH
  Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998 Feb 19;338(8):499-505.
•   Holford SD, Holford NHG, Anderson BJ
  Online dose calculation tool for determining dosing regimens in the very young. PAGANZ website. http://www.paganz.org/wp-content/uploads/2013/01/Online-dose-calculation-tool-for-determining-dosing-regimens-in-the-very-young1.pdf. Accessed July 5, 2013.
•   Imaeda H, Takahashi K, Fujimoto T, Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A
  Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol. 2014 Jan;49(1):100-9. doi: 10.1007/s00535-013-0803-4. Epub 2013 Apr 11.
•   Miskulin DC, Weiner DE, Tighiouart H, Ladik V, Servilla K, Zager PG, Martin A, Johnson HK, Meyer KB; Medical Directors of Dialysis Clinic Inc
  Computerized decision support for EPO dosing in hemodialysis patients. Am J Kidney Dis. 2009 Dec;54(6):1081-8. doi: 10.1053/j.ajkd.2009.07.010. Epub 2009 Sep 25.
•   Montazeri A, Culine S, Laguerre B, Pinguet F, Lokiec F, Albin N, Goupil A, Déporte-Féty R, Bugat R, Canal P, Chatelut E
  Individual adaptive dosing of topotecan in ovarian cancer. Clin Cancer Res. 2002 Feb;8(2):394-9.
•   Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF
  Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53. doi: 10.1016/j.cgh.2008.03.014.
•   Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR
  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010 Jan;59(1):49-54. doi: 10.1136/gut.2009.183095.
•   Shaw G
  Clinical modeling hits prime time. Drug Discovery and Development website. http://www.dddmag.com/articles/2007/09/clinical-modeling-hits-prime-time. Published September 6, 2007. Accessed July, 5 2013.
•   Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA
  Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014 Jun;63(6):919-27. doi: 10.1136/gutjnl-2013-305279. Epub 2013 Jul 22.
•   Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T; RISING study
  Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol. 2009;19(5):478-87. doi: 10.1007/s10165-009-0195-8. Epub 2009 Jul 22.
•   Tobler A, Mühlebach S
  Intravenous phenytoin: a retrospective analysis of Bayesian forecasting versus conventional dosing in patients. Int J Clin Pharm. 2013 Oct;35(5):790-7. doi: 10.1007/s11096-013-9809-5. Epub 2013 Jun 29.
•   Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ; European Crohn's and Colitis Organisation
  European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006 Mar;55 Suppl 1:i16-35.
•   van Lent-Evers NA, Mathôt RA, Geus WP, van Hout BA, Vinks AA
  Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999 Feb;21(1):63-73.
•   Xu Z, Davis HM, Zhou H
  Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther. 2013 Feb;137(2):225-47. doi: 10.1016/j.pharmthera.2012.10.005. Epub 2012 Oct 23. Review.
•   Xu Z, Mould DR, Hu C, Ford J, Keen M, Davis HM, Zhou H
  "A Population-Based Pharmacokinetic Pooled Analysis of Infliximab in Pediatrics" ACCP National Meeting 2012 San Diego CA.

Precision IFX: Using a Pharmacokinetic Dashboard to Optimize and Individualize Infliximab Dosage for Pediatric Inflammatory Bowel Disease Patients

Details for clinical trial NCT02624037